Tuesday, July 1, 2025 7/1/2025

A New Anti-inflammatory Therapy for Ischemic Stroke

Award Number: R42HL156322
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/15/2020
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

A New Anti-inflammatory Therapy for Ischemic Stroke - PROJECT SUMMARY Current therapy for patients with ischemic stroke is limited and new treatment is needed since the mortality and morbidity of this population remain high. Effort aimed at blocking immune cell- mediated inflammation with enhanced inflammation resolution represents a novel approach. The specific background for the proposed project is that we have identified a lead drug candidate through our collaboration with Dr. Kenneth A. Jacobson at NIH and have demonstrated anti-stroke efficacy in an established murine ischemic stroke model and have shown potency in blocking human P2X4R in myeloid cells of healthy subjects. The Company is collaborating with its academic partner University of Connecticut School of Medicine’s research laboratories, and Laboratory of Bioorganic Chemistry of the National Institute of Diabetes, Digestive and Kidney Diseases of NIH. The Company, with its resources, has had STTR Phase 1 funding and should be well positioned to perform IND-enabling studies. The objective of the grant is to conduct IND-enabling process chemistry, GLP manufacturing of the lead compound and safety/toxicity studies. The proposed studies should add to scientific knowledge on the chemistry and pharmacology of P2X4 antagonists and may also yield new insights into the science of such an anti-inflammatory approach. Pending successful outcomes, the proposal should position the Company to prepare an IND application to the FDA.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,109,152 )
2025	2025	CORNOVUS PHARMACEUTICALS INC.	261 SAINT RONAN ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Cardiovascular Diseases Research	001	3	6/12/2025	NON-COMPETING CONTINUATION	$1,109,152
2025	2024	CORNOVUS PHARMACEUTICALS INC.	400 FARMINGTON AVE	FARMINGTON	CT	06032	CAPITOL	USA	Cardiovascular Diseases Research	000	2	10/9/2024	COMPETING CONTINUATION	$0
														Subtotal = $1,109,152

Issue Date FY: 2024 ( Subtotal = $934,548 )
2024	2024	CORNOVUS PHARMACEUTICALS INC.	400 FARMINGTON AVE	FARMINGTON	CT	06032	CAPITOL	USA	Cardiovascular Diseases Research	000	2	9/12/2024	COMPETING CONTINUATION	$934,548
														Subtotal = $934,548

Grand Total All Awards = $2,043,700

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A New Anti-inflammatory Therapy for Ischemic Stroke

Award Number: R42HL156322

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/15/2020

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer